Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

kamiros pty ltd - hydrogen peroxide - algicide - spa | outdoor spa | spa pools - bacteria | clarifier | pool clarifier | spa clarifier

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gliclazide, quantity: 60 mg - tablet, modified release - excipient ingredients: sodium acetate; magnesium stearate; lactose monohydrate; silicon dioxide; mannitol; hypromellose - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gliclazide, quantity: 30 mg - tablet, modified release - excipient ingredients: magnesium stearate; hypromellose; sodium acetate; silicon dioxide; mannitol; lactose monohydrate - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gliclazide, quantity: 30 mg - tablet, modified release - excipient ingredients: hypromellose; magnesium stearate; mannitol; lactose monohydrate; silicon dioxide; sodium acetate - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gliclazide, quantity: 60 mg - tablet, modified release - excipient ingredients: silicon dioxide; mannitol; lactose monohydrate; magnesium stearate; sodium acetate; hypromellose - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

axim pharmaceuticals (pty) ltd - injection - each 10 ml solution contains iopamidol equivalent to 2 g iodine

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

axim pharmaceuticals (pty) ltd - injection - each 20 ml solution contains iopamidol 12,24 g equivalent to 6 g iodine

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

axim pharmaceuticals (pty) ltd - injection - see ingredients - each 50 ml solution contains iopamidol 30,6 g equivalent to 15 g iodine

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

axim pharmaceuticals (pty) ltd - injection - see ingredients - each 100 ml solution contains iopamidol 61,2 g equivalent to 30 g iodine

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

axim pharmaceuticals (pty) ltd - injection - each 20 ml solution contains iopamidol 15,1 g equivalent to 7,4 g iodine